Novartis AG ADR (NVS)vsSemler Scientific Inc (SMLR)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
SMLR
Semler Scientific Inc
$20.33
0.00%
HEALTHCARE · Cap: $348.27M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 131812% more annual revenue ($56.69B vs $42.98M). NVS leads profitability with a 22.5% profit margin vs 0.9%. SMLR trades at a lower P/E of 5.0x. SMLR earns a higher WallStSmart Score of 53/100 (C-).
NVS
Buy51
out of 100
Grade: C-
SMLR
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
+37.1%
Fair Value
$32.33
Current Price
$20.33
$12.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Earnings expanding 3570.1% YoY
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.2% — below average capital efficiency
0.9% margin — thin
Revenue declined 0.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : SMLR
The strongest argument for SMLR centers on P/E Ratio, Price/Book, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : SMLR
The primary concerns for SMLR are Market Cap, Return on Equity, Profit Margin. Thin 0.9% margins leave little buffer for downturns.
Key Dynamics to Monitor
SMLR carries more volatility with a beta of 1.33 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SMLR scores higher overall (53/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Semler Scientific Inc
HEALTHCARE · MEDICAL DEVICES · USA
Semler Scientific, Inc. develops, manufactures, and markets proprietary products that help healthcare providers evaluate and treat patients with chronic conditions in the United States. The company is headquartered in Santa Clara, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?